{"nctId":"NCT04295681","briefTitle":"Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders","startDateStruct":{"date":"2019-12-12","type":"ACTUAL"},"conditions":["Cognitive Disorders"],"count":246,"armGroups":[{"label":"MMH-MAP","type":"EXPERIMENTAL","interventionNames":["Drug: MMH-MAP"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"MMH-MAP","otherNames":["Prospekta"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age between 40 and 75 years old inclusively.\n2. Ischemic stroke in the carotid arteries (I 63) within 72 hours post debut.\n3. Moderate cognitive disorders (MoCA \\< 26).\n4. Normal consciousness (Glasgow score 15)\n5. Stroke severity 8-12 according to NIHSS.\n6. Disability mRs score 2-3.\n7. Availability of cerebral CT/MRI within 72 hours post stroke debut.\n8. Patients who agreed to use a reliable method of contraception during the study.\n9. Patients who have signed the Participant Information Sheet and Informed Consent.\n\nExclusion Criteria:\n\n1. Current or previous subarachnoidal/parenchymatous/ventricular hemorrhage, cerebral infarction, cerebral tumour.\n2. Cerebral CT/MRI findings suggesting cerebral hemorrhage, tumour within 72 hours post stroke debut.\n3. Scheduled or completed thrombolytic therapy for the treatment of the current cerebral infarction.\n4. Central nervous system (CNS) diseases including:\n\n   * Inflammatory diseases of the central nervous system (G00-G09);\n   * Systemic atrophies primarily affecting the central nervous system (G10-G13);\n   * Extrapyramidal and movement disorders (G20-G26);\n   * Other degenerative diseases of the nervous system (G30-G32);\n   * Demyelinating diseases of the CNS (G35-G37);\n   * Episodic and paroxysmal disorders (G40-G47);\n   * Polyneuropathies and other disorders of the peripheral nervous system (G60-64), with marked movement and/or sensory impairments that cause movement disorders;\n   * Hydrocephalus (G91).\n5. Head injuries (S00-S09) (including history), accompanied by impaired consciousness, brain contusion or open craniocerebral injuries.\n6. Musculoskeletal disorders causing motor disturbances.\n7. Dementia (including history) (F00-F03).\n8. Malignant neoplasms.\n9. Patients previously diagnosed with class IV heart failure (1964 New York Heart Association functional classification), hypothyroidism, or poorly treated diabetes mellitus.\n10. Patients having unstable angina or myocardial infarction in the past 6 months.\n11. Allergy/ intolerance to any of the components of medications used in the treatment.\n12. Malabsorption syndrome, including congenital or acquired lactase deficiency (or any other disaccharidase deficiency) and galactosemia.\n13. Any conditions which, according to the investigator opinion, may interfere with the subject's participation in the study.\n14. Prior history of non-adherence to a drug regimen, a psychiatric disorder, alcoholism or drug abuse, which, in the opinion of the investigator, can compromise compliance with study protocol.\n15. Pregnancy, breast-feeding; childbirth less than 3 months prior to the inclusion in the trial, unwillingness to use contraceptive methods during the trial.\n16. Participation in other clinical studies within 3 month prior to enrollment in the study.\n17. Patients who are related to any of the on-site research personnel directly involved in the conduct of the trial or are an immediate relative of the study investigator. 'Immediate relative' means husband, wife, parent, son, daughter, brother, or sister (regardless of whether they are natural or adopted).\n18. Patients who work for OOO \"NPF \"Materia Medica Holding\" (i.e. the company's employees, temporary contract workers, designated officials responsible for carrying out the research or any immediate relatives of the aforementioned).","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Average MoCA Score.","description":"Montreal Cognitive Assessment Scale (The Montreal Cognitive Assessment, MoCA) will be used to identify moderate cognitive impairment, as well as to assess changes in cognitive functions during therapy. The maximum possible number of points is 30; 26 points or more is considered normal. The minimum score is 0, higher score is better.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.7","spread":"3.5"},{"groupId":"OG001","value":"21.7","spread":"2.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":"2.9"},{"groupId":"OG001","value":"24.5","spread":"3.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"2.5"},{"groupId":"OG001","value":"2.9","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Changes in NIHSS Score.","description":"NIHSS Scale (National Institutes of Health Stroke Scale) is a scale for assessing the severity of neurological disorders of the acute period of ischemic stroke. The NIHSS scale involves the assessment of a neurological condition by generally accepted methods of clinical examination of reflexes, sensory organs, and the patient's level of consciousness. The results range from minimum indicators - normal or close to normal, to maximum - reflect the degree of neurological damage. The score varies between 0 and 42, lower score is better.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":"0.8"},{"groupId":"OG001","value":"8.5","spread":"0.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"2.0"},{"groupId":"OG001","value":"4.8","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"1.8"},{"groupId":"OG001","value":"2.9","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"1.7"},{"groupId":"OG001","value":"3.7","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"1.7"},{"groupId":"OG001","value":"5.6","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With no Significant Disabilities.","description":"The modified Rankin scale (mRs 0-1) allows to assess the grade of disability after a stroke. The scale includes five grades of disability: from 0 to 5: 0 - no symptoms, 5 - gross disability; bedridden, fecal and urinary incontinence, need for constant assistance by medical staff.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Therapeutic and Side Effects, Efficacy Index.","description":"According to Clinical Global Impression Efficacy Index (CGI-EI).CGI-EI is filled out by an investigator. It is necessary to indicate the level of efficacy of the therapy and the grade of safety of the therapy and circle the index values at the intersection of the selected lines. Evaluation of the response to treatment should take into account both therapeutic efficacy and treatment-related side effects. Side effects score varies from 1 to 4 (lower is better). Therapeutic effect score varies from 1 to 4 (higher is better). The efficacy index is \"Therapeutic effect score\" divided by \"Side effects score\", so efficacy index varies from 0.25 to 4 (higher is better).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"0.6"},{"groupId":"OG001","value":"3.1","spread":"0.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"0.4"},{"groupId":"OG001","value":"1.2","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"0.8"},{"groupId":"OG001","value":"2.8","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Presence of Adverse Events (AEs).","description":"Based on medical records. Outcome measure represents the amount of participants having at least one adverse event on record.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Complication of Cerebral Infarction.","description":"Based on medical records. The sequelae of cerebral infarction (severe infections - hospital-acquired pneumonia, uroinfection; deep venous thrombosis, PATE; epileptic episodes).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Death Rate.","description":"Based on medical records. Frequency of all-cause mortality outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in Vital Signs (Pulse Rate (Heart Rate)).","description":"Based on medical records. Vital signs will be measured in a medical setting.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.0","spread":"7.6"},{"groupId":"OG001","value":"73.5","spread":"7.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.3","spread":"5.4"},{"groupId":"OG001","value":"71.3","spread":"6.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.3","spread":"6.1"},{"groupId":"OG001","value":"71.4","spread":"5.4"}]}]}]},{"type":"SECONDARY","title":"Changes in Vital Signs (Respiration Rate (Breathing Rate)).","description":"Based on medical records. Vital signs will be measured in a medical setting.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","spread":"1.0"},{"groupId":"OG001","value":"16.8","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":"1.0"},{"groupId":"OG001","value":"16.7","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","spread":"1.1"},{"groupId":"OG001","value":"16.8","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Changes in Vital Signs (Blood Pressure).","description":"Based on medical records. Vital signs are measured in a medical setting. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":"12.6"},{"groupId":"OG001","value":"139.0","spread":"11.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":"8.3"},{"groupId":"OG001","value":"130","spread":"7.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":"7.7"},{"groupId":"OG001","value":"130","spread":"7.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.9","spread":"7.0"},{"groupId":"OG001","value":"83.5","spread":"7.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":"5.5"},{"groupId":"OG001","value":"80.6","spread":"5.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.2","spread":"5.3"},{"groupId":"OG001","value":"80.0","spread":"6.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Clinically Significant Abnormal Laboratory Data.","description":"Based on medical records. Laboratory tests include the following parameters (absolute and relative values): hematology, biochemistry and urinalysis. Laboratory tests will be made by central laboratory. Hemoglobin: less than or equal to (\\<=) 115 grams per liter (g/L); greater than or equal to (\\>=)185 g/L; decreased from baseline (DFB) \\>=20 g/L Hematocrit: \\<=0.37 volume/volume (v/v); \\>=0.55 v/v Erythrocytes: \\>=6 Tera/L Leukocytes: \\>=16.0 Giga/L Neutrophils: \\<1.0 Giga/L (B); Lymphocytes: greater than (\\>) 4.0 Giga/L Monocytes: \\>0.7 Giga/L Basophils: \\>0.1 Giga/L Eosinophils: \\>0.5 Giga/L or \\>upper limit of normal (ULN) (if ULN \\>=0.5 Giga/L) Sodium: \\<=129 millimoles (mmol)/L; \\>=160 mmol/L Potassium: \\<3 mmol/L; \\>=5.5 mmol/L Alanine Aminotransferase (ALT): \\>3 ULN Aspartate aminotransferase (AST): \\>3 ULN Alkaline phosphatase: \\>1.5 ULN Bilirubin: \\>1.5 ULN Creatinine: \\>=150 micromoles per liter (mcmol/L); \\>=30% change from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Recurring Cerebral Infarction.","description":"The percentage of patients with recurrent cerebral infarction for 90 days of the treatment period is estimated from medical records.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":123},"commonTop":["Increased blood pressure","Asthenia","Headache","Bronchitis","Coronavirus infection COVID-19"]}}}